Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Angle (AGL)

Price 8.00p on 09-10-2024 at 16:30:02
Change 0.00p 0%
Buy 8.50p
Sell 7.50p
Buy / Sell AGL Shares
Last Trade: Unknown 12,531.00 at 8.00p
Day's Volume: 815,704
Last Close: 8.00p
Open: 8.00p
ISIN: GB0034330679
Day's Range 8.00p - 8.00p
52wk Range: 7.50p - 31.40p
Market Capitalisation: £26m
VWAP: 8.096508p
Shares in Issue: 323m

Recent Trades History Angle (AGL)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 12,531 8.00p OTC Trade
17:05:28 - 09-Oct-24
Unknown* 50,000 7.525p OTC Trade
16:06:46 - 09-Oct-24
Unknown* 50,000 7.50p OTC Trade
16:06:27 - 09-Oct-24
Unknown* 5,000 8.00p Ordinary
15:57:24 - 09-Oct-24
Unknown* 70,363 8.00p Ordinary
15:48:03 - 09-Oct-24
Buy* 36,257 8.2495p Ordinary
15:46:40 - 09-Oct-24
Buy* 20,000 8.2495p Ordinary
15:22:52 - 09-Oct-24
Buy* 50,000 8.25p Ordinary
15:20:23 - 09-Oct-24
Buy* 12,060 8.25p Ordinary
15:16:58 - 09-Oct-24
Buy* 1,119 8.25p Ordinary
14:58:19 - 09-Oct-24

Share Price History for Angle

Time period:
to
Date Open High Low Close Volume

Share News for Angle

EARNINGS: Ebiquity bemoans poor conditions on swing to interim loss

26th Sep 2024 13:30

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

19th Sep 2024 14:44

Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a clinical-stage biotech company. It will launch with a fully-funded pilot study. Further details are confidential between the two companies. Read More

IN BRIEF: Angle hails publication of research data in science journal

23rd Aug 2024 11:43

Angle PLC - Guildford, England-based liquid biopsy company - Celebrates research data on its Parsortix PC1 system that it says supports approval by the US Food & Drug Administration. Data was published as a peer-reviewed publication in the Journal of Experimental & Clinical Research. The study had been submitted to the FDA for De Novo clearance of the Parsortix PC1 system. The De Novo process provides a pathway to classify some novel medical devices. The study reports that the Parsortix system successfully captured and harvested circulating tumour cells (CTC) from metastatic breast cancer patient blood samples for downstream analysis using immunofluorescence and cytological evaluation. Angle says the publication validates the use of the Parsortix system for CTC isolation and harvest in metastatic breast cancer. Read More

UK shareholder meetings calendar - next 7 days

4th Jul 2024 12:13

Read More

IN BRIEF: Angle says open offer raises proceeds of GBP500,000

21st Jun 2024 10:52

Angle PLC - Guildford, England-based liquid biopsy company - Receives valid applications for a total of 3.6 million open offer shares from qualifying shareholders, pursuant to open offer announced on June 5. Says that the open offer has raised gross proceeds of GBP500,000 at the issue price, which will be used to strengthen Angle's balance sheet. Adds that in aggregate, GBP9.3 million gross proceeds have been raised, pursuant to the placing, subscription, and open offer. Read More

FTSE 100 Latest
Value8,243.74
Change53.13

Login to your account

Forgot Password?

Not Registered